How does Real-World Evidence Impact Medicinal Product Development in Europe?
Explore the growing role of Real-World Evidence (RWE) in the regulatory decision-making process for medicinal products in Europe. Learn how RWE is...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
Based on an online seminar presentation made in collaboration with TOPRA and Veristat, this article dives into the future of the European medicines and medical devices industry and the changes in legislation that are being prompted by the evolving pharmaceutical environment. 
On 25 November 2020, the European Commission (EC) adopted the patient-centric New Pharmaceutical Strategy for Europe and published its roadmap for the revision of the general pharmaceutical legislation in 2021. The European Commission has begun initiating work in several areas, including the pediatric and orphan review.
In this article, you will get a comprehensive overview of the following:
Read the full article to learn more: https://www.regulatoryrapporteur.org/european-medicines-and-medical-devices-future-trends/222.article
Explore the growing role of Real-World Evidence (RWE) in the regulatory decision-making process for medicinal products in Europe. Learn how RWE is...
This year, our webinar centered on the challenges and opportunities associated with bringing novel medicinal products to market. No one in the...
Learn about the impact of the new EU Medical Device Regulation (MDR) on the development of medical devices and drug-device combination products. Gain...